Bio-Rad Laboratories (NYSE:BIO) this week said it acquired Celsee for an undisclosed amount.
Celsee develops instruments and consumables for the isolation, detection and analysis of single cells. The company’s Genesis System allows scientists to isolate, analyze and interpret cellular behavior and collect cell-based information for improved results in single-cell cytometry, single-cell transcriptomics, single-cell multiomics, rare-cell enrichment and enumeration.
“We are pleased to have Celsee join Bio-Rad,” Bio-Rad president and CEO Norman Schwartz said in a news release. “Their innovative products and technologies will extend our reach into the rapidly growing world of precision medicine and single-cell analysis, both of which offer enhanced insight into disease, diagnosis and treatment.”
Bio-Rad earlier this week launched a blood-based immunoassay kit to help identify COVID-19 antibodies.